NCT01975389,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016"
NCT01975376,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016"
NCT02488967,NRG Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02311933,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016"
NCT02439320,CoLucid Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02439320,True,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],"November 13, 2015"
NCT00351611,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016"
NCT02150577,University of Arkansas,True,AR,https://ClinicalTrials.gov/show/NCT02150577,True,Implementation Trial of Evidence Based Practices for Mood Disorders,Bipolar Disorder; Treatment Resistant Depression,Behavioral:Evidence Based Quality Improvement,"[u'Mainline Health Systems Inc.', u'Boston Mountain Rural Health Center', u'Lee County Cooperative Clinic', u'ARcare', u'Jefferson Comprehensive Care System', u'East Arkansas Family Health Center']","October 14, 2015"
NCT02674386,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016"
NCT02673190,Radiation Therapy Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016"
NCT02488967,NRG Oncology,False,CO,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02229539,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015"
NCT01272037,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02194738,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT01674140,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016"
NCT01272037,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02674386,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016"
NCT02545049,Bayer,False,FL,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016"
NCT02451137,Sanofi,False,GA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016"
NCT01272037,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02488967,NRG Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02311933,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016"
NCT01120249,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015"
NCT01272037,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02562716,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016"
NCT02523014,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015"
NCT02101788,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016"
NCT01349881,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015"
NCT02488967,NRG Oncology,False,IA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02194738,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT02488967,NRG Oncology,False,KS,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02194738,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT01272037,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02488967,NRG Oncology,False,KY,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT01272037,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT01674140,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016"
NCT02155296,RAND,False,ME,https://ClinicalTrials.gov/show/NCT02155296,True,RCT of the Restorative Practices Intervention,Intervention Schools (Schools Receiving RPI); Control Schools (Schools Not Receiving RPI),Behavioral:Restorative Practices Intervention,"[u'Bath Middle School', u'Boothbay school', u'Bucksport school', u'Bonny Eagle school', u'Ridge View school', u'Hall-Dale school', u'Molly Ockett', u'Gorham school', u'Hope school', u'Jefferson Village school', u'Mt. Jefferson school', u'Libby school', u'Maranacook school', u'Oak Hill school', u'Skowhegan school', u'Windham school']","October 27, 2015"
NCT02194738,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT01674140,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016"
NCT01272037,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT01272037,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02194738,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT02673190,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016"
NCT02488967,NRG Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02488967,NRG Oncology,False,MN,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02315469,NRG Oncology,False,MN,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015"
NCT01991795,AstraZeneca,False,MS,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016"
NCT01953588,Alliance for Clinical Trials in Oncology,False,MS,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015"
NCT02562716,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016"
NCT02488967,NRG Oncology,False,MO,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT00843882,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016"
NCT01272037,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02194738,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT02193282,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016"
NCT02601209,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016"
NCT02488967,NRG Oncology,False,NV,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT01272037,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT01949337,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015"
NCT01674140,Southwest Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016"
NCT01272037,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT01674140,Southwest Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016"
NCT02115282,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016"
NCT02194738,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT02193282,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016"
NCT02451137,Sanofi,False,NC,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016"
NCT02311933,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016"
NCT01107626,Eastern Cooperative Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012"
NCT01274338,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016"
NCT02673190,Radiation Therapy Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016"
NCT02562716,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016"
NCT01272037,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT01674140,Southwest Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016"
NCT01272037,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT01674140,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016"
NCT02488967,NRG Oncology,False,PA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02406677,AstraZeneca,False,PA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016"
NCT01272037,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02194738,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT02194738,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT02193282,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016"
NCT01272037,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT01120249,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015"
NCT01272037,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02343406,AbbVie,False,TN,https://ClinicalTrials.gov/show/NCT02343406,True,ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,Glioblastoma Multiforme,Drug:ABT-414; Drug:Lomustine; Drug:Temozolomide,[],"January 7, 2016"
NCT02574078,Bristol-Myers Squibb,False,TX,https://ClinicalTrials.gov/show/NCT02574078,True,A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),Non-Small Cell Lung Cancer,Drug:Nivolumab; Drug:Bevacizumab; Drug:Pemetrexed; Other:Palliative radiation; Drug:nab-Paclitaxel; Drug:Paclitaxel; Drug:Docetaxel; Drug:Gemcitabine; Drug:Erlotinib; Drug:Crizotinib; Drug:Carboplatin,[],"January 26, 2016"
NCT01272037,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02488967,NRG Oncology,False,UT,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02673190,Radiation Therapy Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016"
NCT02194738,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016"
NCT01674140,Southwest Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016"
NCT01272037,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02488967,NRG Oncology,False,WA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016"
NCT02375204,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015"
NCT01674140,Southwest Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016"
NCT01272037,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT02673190,Radiation Therapy Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016"
NCT02523014,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015"
NCT02048813,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016"
NCT02003209,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016"
NCT00373685,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012"
NCT00264901,Novo Nordisk A/S,False,AL,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014"
NCT00743652,Pfizer,False,AK,https://ClinicalTrials.gov/show/NCT00743652,False,Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.,Pneumococcal Disease; 13-valent Pneumococcal Vaccine,Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine,"[u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site']","March 13, 2012"
NCT02465060,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT00346216,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016"
NCT00264901,Novo Nordisk A/S,False,AZ,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014"
NCT00264901,Novo Nordisk A/S,False,AR,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014"
NCT02604836,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02604836,False,A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia,Postmenopausal Osteoporosis,Drug:Ibandronate,[],"February 1, 2016"
NCT02649478,Roxane Laboratories,False,CA,https://ClinicalTrials.gov/show/NCT02649478,False,Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate,Asthma,Drug:Fluticasone / Salmeterol; Drug:Placebo; Drug:Advair Diskus 100/50,[],"January 13, 2016"
NCT02500797,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016"
NCT02500797,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016"
NCT02465060,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT01691430,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT01691430,False,A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents,Bacteriuria,Dietary Supplement:2 cranberry capsules; Dietary Supplement:Placebo,"[u'Branford Hills Health Care', u'Northbridge Health Care Center', u'Bridgeport Health Care Center', u'Bridgeport Manor', u'Riverside Health & Rehabilitation Center', u'Ludlowe Health Care Center', u'Glastonbury Health Care Center', u'The Nathaniel Witherell', u'Hamden Health Care Center', u'Arden House Care and Rehabilitation Center', u'Avery Heights', u'Wadsworth Glen Health Care and Rehabilitation Center', u""Water's Edge Center for Health & Rehabilitation"", u'Mary Wade Home', u'Advanced Nursing & Rehab Center of New Haven', u'Grimes Center', u'Shady Knoll Health Center', u'Lord Chamberlain Nursing & Rehabilitation Center', u'Village Green of Wallingford', u'Abbott Terrace Health Center', u'Hughes Health & Rehab Center']","October 22, 2015"
NCT00034879,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013"
NCT01275677,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016"
NCT00946712,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015"
NCT02245568,TauRx Therapeutics Ltd,False,FL,https://ClinicalTrials.gov/show/NCT02245568,False,Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD),Alzheimer's Disease; Behavioral Variant Frontotemporal Dementia,Drug:TRx0237,[],"September 17, 2014"
NCT02139046,Takeda,False,FL,https://ClinicalTrials.gov/show/NCT02139046,False,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Drug:Febuxostat IR; Drug:Febuxostat XR; Drug:Febuxostat placebo; Drug:Colchicine; Drug:Naproxen; Drug:Lansoprazole,[],"November 13, 2015"
NCT01306890,Dendreon,False,GA,https://ClinicalTrials.gov/show/NCT01306890,False,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Advanced Prostate Cancer; Prostatic Neoplasms,Biological:sipuleucel-T,[],"October 5, 2015"
NCT01275677,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016"
NCT02465060,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT01041781,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015"
NCT02465060,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT01886872,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016"
NCT02500797,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016"
NCT02465060,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT01658943,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015"
NCT01642251,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016"
NCT02196181,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016"
NCT01886872,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016"
NCT02311907,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015"
NCT02224781,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02224781,False,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],"February 4, 2016"
NCT01275677,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016"
NCT02196181,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016"
NCT02465060,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT01327846,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01327846,False,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],"May 19, 2015"
NCT00310180,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT01275677,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016"
NCT01275677,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016"
NCT00346216,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016"
NCT01454947,University of Southern California,False,MA,https://ClinicalTrials.gov/show/NCT01454947,False,Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study),Acute Respiratory Infections (ARIs),Behavioral:Clinical Decision Support: Justification Alerts; Behavioral:Audit and Feedback: Social Norms; Behavioral:CDS Order Sets: Alternative Prescriptions,[],"November 2, 2011"
NCT00382070,NSABP Foundation Inc,True,MA,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014"
NCT02465060,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT02311907,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015"
NCT02500797,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016"
NCT02465060,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT00264901,Novo Nordisk A/S,False,MS,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014"
NCT00373685,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012"
NCT02465060,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT02196181,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016"
NCT02311907,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015"
NCT00951496,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016"
NCT01275677,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016"
NCT00769379,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016"
NCT02500797,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016"
NCT02465060,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT02515981,Dartmouth-Hitchcock Medical Center,False,NH,https://ClinicalTrials.gov/show/NCT02515981,False,New Hampshire Medicaid Wellness Incentive Program,Tobacco Dependence; Obesity; Mental Illness,Behavioral:NH Medicaid Incentives Program,"[u'New Hampshire Hospital', u'Riverbend Community Mental Health Center', u'Center for Life Management', u'Community Partners', u'Mondadnock Family Services', u'West Central Behavioral Health Care', u'Northern Human Services', u'The Mental Health Center of Greater Manchester', u'Greater Nashua Mental Health Center at Community Council', u'Harbor Homes', u'Genesis Behavioral Heatlh', u'Seacoast Mental Health Center']","January 21, 2016"
NCT00769379,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016"
NCT00769379,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016"
NCT00658515,Hoffmann-La Roche,False,NJ,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016"
NCT00264901,Novo Nordisk A/S,False,NM,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014"
NCT00079274,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015"
NCT01835158,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016"
NCT01547741,NSABP Foundation Inc,False,NY,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015"
NCT02465060,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT02196181,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016"
NCT01041781,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015"
NCT00892177,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00892177,False,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],"November 23, 2015"
NCT02465060,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT02315430,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016"
NCT00769379,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016"
NCT01275677,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016"
NCT00769379,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016"
NCT00324805,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016"
NCT02465060,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT01886872,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016"
NCT00310180,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT00346216,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016"
NCT02465060,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT01886872,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016"
NCT00601900,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015"
NCT00433511,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016"
NCT00310180,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016"
NCT00264901,Novo Nordisk A/S,False,TN,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014"
NCT02122471,Synergy Pharmaceuticals Inc.,False,TX,https://ClinicalTrials.gov/show/NCT02122471,False,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 29, 2015"
NCT02030600,Novo Nordisk A/S,False,TX,https://ClinicalTrials.gov/show/NCT02030600,False,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes","Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],"December 8, 2015"
NCT01546844,HealthInsight,False,UT,https://ClinicalTrials.gov/show/NCT01546844,False,Mobile Health Technology as an Intervention for Diabetes Self-Management,Type II Diabetes Mellitus,Other:Participation in Care4Life,"[u'Coalville Health Center', u'Pioneer Comprehensive Medical', u'Olympus Clinic', u'Holladay Family Practice', u'Exodus Healthcare - Main Office - Magna', u'Community Health Centers Inc. - 72nd Street Clinic', u'Park City Healthcare, Inc.', u'Riverton Family Health Center', u'Granger Medical-Riverton', u'Health Clinic Of Utah - SLC', u'Alpine Internal Medicine', u'HealthInsight', u'Central City Community Health Center Health First Family Medicine', u'Evolutionary Healthcare, Llc', u""Utah Physicians Care Centers - St Mark's Internal Medicine"", u'Stephen D. Ratcliffe Community Health Center', u'Jordan Ridge Family Medicine', u""Utah Healthcare Institute - St. Mark's Family Medicine"", u'Wasatch Homeless Health Care - 4th Street Clinic', u'Wasatch Internal Medicine', u'Barbara E. Rizzardi, M.D.', u'Copperview Medical Center, Llc', u'Community Health Centers Inc. - Oquirrh View', u'Advanced Practice Medical Clinic', u'Valley Family Medicine', u'Jordan Meadows Medical Center', u'Granger Medical - Jordan Medical Arts', u'Granger Medical Clinic Inc. - Main Office', u'Kathryn Allen, MD', u'West Valley Family And Preventive Medicine']","September 4, 2012"
NCT02199691,"Sanofi Pasteur, a Sanofi Company",False,UT,https://ClinicalTrials.gov/show/NCT02199691,False,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents,Meningitis; Meningococcal Meningitis; Meningococcal Infections,"Biological:Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine; Biological:Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197Conjugate Vaccine; Biological:Adacel: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Biological:GARDASIL: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant; Biological:Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine; Biological:Adacel: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Biological:GARDASIL: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant",[],"November 5, 2015"
NCT01004640,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT01004640,False,Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial,Leukemia,Genetic:DNA analysis; Genetic:Southern blotting; Genetic:cytogenetic analysis; Genetic:polymerase chain reaction,[],"July 23, 2015"
NCT00372996,Pfizer,False,VT,https://ClinicalTrials.gov/show/NCT00372996,False,"Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer",Breast Neoplasms,"Drug:CP-751,871; Drug:exemestane; Drug:exemestane; Drug:Fulvestrant",[],"October 6, 2015"
NCT01547741,NSABP Foundation Inc,False,VA,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015"
NCT01275677,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016"
NCT02465060,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT02315430,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016"
NCT00264901,Novo Nordisk A/S,False,WV,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014"
NCT01961037,West Virginia University,False,WV,https://ClinicalTrials.gov/show/NCT01961037,False,Translation of an Evidence-Based Fall-Prevention Program Into Rural West Virginia Churches,Accidental Falls,Other:Tai Chi: Moving for Better Balance,"[u'Hughes River Presbyterian Church', u'Wesley United Methodist Church', u'Harper Memorial Church', u'First Baptist Church', u'First Assembly of God', u'Cisco Community Church', u'First Baptist Church', u'Memorial United Methodist Church', u'Spencer Presbyterian Church']","December 22, 2015"
NCT02465060,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016"
NCT02315430,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016"
NCT01886872,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016"
NCT01835158,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016"
